Ambrx Biopharma, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Material events
SEC Form 8-K · most recent- Director / officer changeMar 12, 2024
- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 7, 2024
- Shareholder vote · Regulation FD disclosureMar 6, 2024
- Other material eventFeb 22, 2024
- Entered a material agreement · Regulation FD disclosureJan 8, 2024
- Director / officer changeDec 1, 2023
- Other material eventOct 23, 2023
- Other material eventOct 16, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.